Thomas Mahaffey, OD
Optometrist · Bloomington, ILNPI 1669401139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $538, 3.0 times the $179 reported in 2019.
Across 100 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$466
- Novartis$269
- Harrow Eye, LLC$252
- Mallinckrodt Hospital Products Inc.$173
- Oyster Point Pharma, Inc.$133
- Tarsus Pharmaceuticals, Inc.$110
- plus $619 from 13 others
What the payments were for
- Food & beverage$2,021100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 19 | $466 |
| Novartis | 17 | $269 |
| Harrow Eye, LLC | 11 | $252 |
| Mallinckrodt Hospital Products Inc. | 7 | $173 |
| Oyster Point Pharma, Inc. | 7 | $133 |
| Tarsus Pharmaceuticals, Inc. | 6 | $110 |
| Alcon | 6 | $96 |
| AbbVie(2 entities) | 5 | $90 |
| Glaukos Corporation | 3 | $77 |
| Sun Pharmaceutical Industries Inc. | 3 | $66 |
| Shire North American Group Inc | 2 | $50 |
| Coopervision Inc. | 3 | $41 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Kala Pharmaceuticals, Inc. | 2 | $34 |
| Aerie Pharmaceuticals, Inc. | 2 | $29 |
| Dompe US, Inc. | 1 | $23 |
| Quidel Corporation | 1 | $20 |
| Amgen | 1 | $19 |
How this compares
$2,021 in reported general payments places this provider in the 80th percentile of 2,257 optometrist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 76 | $690 |
| Latanoprost | 68 | $672 |
| Prednisolone Acetate | 12 | $386 |
| Amoxicillin | 15 | $22 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Bloomington
- Wilson MovicBloomington$91K
- Bradley GrantBloomington$9K
- Pamela LoweChicago$447K
- Jeffrey LewisChampaign$394K
- Adeyinka AdewaleGodfrey$391K
- Michael ChaglasianChicago$367K
- Jessilin QuintChicago$366K
- Jullian CerasuoloChicago$329K
- Steven EidenDeerfield$259K
- Peter KehoeGalesburg$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.